CN  /  EN

imgboxbg

NEWS

最新消息

Another pharmaceutical giant enters the field of CD47

  • 分類:最新消息
  • 作者:華訊知識產權
  • 來源:
  • 發布時間:2020-09-18 13:29
  • 訪問量:

【概要描述】On September 8, 2020, Pfizer made a US$25 million equity investment in Trillium Therapeutics. However, this investment by Pfizer has nothing to do with any partners or pre-emptive rights acquired by Trillium Therapeutics, and these options remain completely open. So, what kind of assets are attracting Pfizer? CD47 is a glycoprotein widely expressed on the surface of a variety of cells. It releases a "don't eat me" signal by connecting with SIRPα on the surface of phagocytes to prevent macrophages from engulfing healthy cells.However, cancer cells cunningly use this mechanism to induce immunosuppression and escape the phagocytosis of macrophages.In recent years, CD47 has gradually become a star target in the field of immuno-oncology, and investment in this field has also shown substantial growth: Trillium Therapeutics is a Canada-based immuno-oncology company dedicated to the development of innovative immunotherapies for the treatment of cancer. The company's clinical projects TTI-621 and TTI-622 are two unique SIRPαFc decoy receptors that can target CD47 and block its activity. TTI-622 is a SIRPa-IgG4-Fc fusion protein, similar to the candidate drug of I-Mab, it has very weak binding to normal red blood cells and does not cause hemagglutination. Current data show that in patients with relapsed/refractory DLBCL who have previously received multiple therapies, TTI-622 has achieved "comparable" results in a joint study with the highest dose of competing products. At the same time, the research results also show that "not all IgG4 are equal", because Xinji terminated its phase I study of its IgG4-CD47 molecule CC-90002 two years ago, and the data of TTI-622 is obviously better than analysts expected. However, using solid single-drug data as a basis makes managers more confident that their drugs will perform better in the combination. TTI-621 is a SIRPa-IgG1-Fc fusion protein, which is characterized by a very low dose to achieve great results. Now, the 1.4 mg/kg dose has been considered to be well tolerated in patients with advanced relapsed/refractory hematological cancers. Trillium Therapeutics plans to continue to evaluate these two projects. Ultimately, the company plans to enter the solid tumor field, and its CEO Jan Skvarka said that Pfizer is very interested in this field. With the revival of interest in CD47 in the pharmaceutical industry, innovative therapies for the CD47-SIRPα pathway are expected to become another fertile new world in the field of tumor immunity.

Another pharmaceutical giant enters the field of CD47

【概要描述】On September 8, 2020, Pfizer made a US$25 million equity investment in Trillium Therapeutics. However, this investment by Pfizer has nothing to do with any partners or pre-emptive rights acquired by Trillium Therapeutics, and these options remain completely open. So, what kind of assets are attracting Pfizer?



CD47 is a glycoprotein widely expressed on the surface of a variety of cells. It releases a "don't eat me" signal by connecting with SIRPα on the surface of phagocytes to prevent macrophages from engulfing healthy cells.However, cancer cells cunningly use this mechanism to induce immunosuppression and escape the phagocytosis of macrophages.In recent years, CD47 has gradually become a star target in the field of immuno-oncology, and investment in this field has also shown substantial growth:



Trillium Therapeutics is a Canada-based immuno-oncology company dedicated to the development of innovative immunotherapies for the treatment of cancer. The company's clinical projects TTI-621 and TTI-622 are two unique SIRPαFc decoy receptors that can target CD47 and block its activity.

TTI-622 is a SIRPa-IgG4-Fc fusion protein, similar to the candidate drug of I-Mab, it has very weak binding to normal red blood cells and does not cause hemagglutination. Current data show that in patients with relapsed/refractory DLBCL who have previously received multiple therapies, TTI-622 has achieved "comparable" results in a joint study with the highest dose of competing products. At the same time, the research results also show that "not all IgG4 are equal", because Xinji terminated its phase I study of its IgG4-CD47 molecule CC-90002 two years ago, and the data of TTI-622 is obviously better than analysts expected. However, using solid single-drug data as a basis makes managers more confident that their drugs will perform better in the combination.



TTI-621 is a SIRPa-IgG1-Fc fusion protein, which is characterized by a very low dose to achieve great results. Now, the 1.4 mg/kg dose has been considered to be well tolerated in patients with advanced relapsed/refractory hematological cancers.

Trillium Therapeutics plans to continue to evaluate these two projects. Ultimately, the company plans to enter the solid tumor field, and its CEO Jan Skvarka said that Pfizer is very interested in this field.

With the revival of interest in CD47 in the pharmaceutical industry, innovative therapies for the CD47-SIRPα pathway are expected to become another fertile new world in the field of tumor immunity.

  • 分類:最新消息
  • 作者:華訊知識產權
  • 來源:
  • 發布時間:2020-09-18 13:29
  • 訪問量:
詳情

On September 8, 2020, Pfizer made a US$25 million equity investment in Trillium Therapeutics. However, this investment by Pfizer has nothing to do with any partners or pre-emptive rights acquired by Trillium Therapeutics, and these options remain completely open. So, what kind of assets are attracting Pfizer?

CD47 is a glycoprotein widely expressed on the surface of a variety of cells. It releases a "don't eat me" signal by connecting with SIRPα on the surface of phagocytes to prevent macrophages from engulfing healthy cells.However, cancer cells cunningly use this mechanism to induce immunosuppression and escape the phagocytosis of macrophages.In recent years, CD47 has gradually become a star target in the field of immuno-oncology, and investment in this field has also shown substantial growth:

Trillium Therapeutics is a Canada-based immuno-oncology company dedicated to the development of innovative immunotherapies for the treatment of cancer. The company's clinical projects TTI-621 and TTI-622 are two unique SIRPαFc decoy receptors that can target CD47 and block its activity.

TTI-622 is a SIRPa-IgG4-Fc fusion protein, similar to the candidate drug of I-Mab, it has very weak binding to normal red blood cells and does not cause hemagglutination. Current data show that in patients with relapsed/refractory DLBCL who have previously received multiple therapies, TTI-622 has achieved "comparable" results in a joint study with the highest dose of competing products. At the same time, the research results also show that "not all IgG4 are equal", because Xinji terminated its phase I study of its IgG4-CD47 molecule CC-90002 two years ago, and the data of TTI-622 is obviously better than analysts expected. However, using solid single-drug data as a basis makes managers more confident that their drugs will perform better in the combination.

TTI-621 is a SIRPa-IgG1-Fc fusion protein, which is characterized by a very low dose to achieve great results. Now, the 1.4 mg/kg dose has been considered to be well tolerated in patients with advanced relapsed/refractory hematological cancers.

Trillium Therapeutics plans to continue to evaluate these two projects. Ultimately, the company plans to enter the solid tumor field, and its CEO Jan Skvarka said that Pfizer is very interested in this field.

With the revival of interest in CD47 in the pharmaceutical industry, innovative therapies for the CD47-SIRPα pathway are expected to become another fertile new world in the field of tumor immunity.

關鍵詞:

上一頁
1
2
...
171
這是描述信息

江蘇省南京市江北新區江淼路88號騰飛大廈B座20層2001

版權所有◎南京華訊知識產權顧問有限公司

備案號:蘇ICP備xxxxxx號-1    網站建設:中企動力 南京

五月天色